DOI: 10.1007/s13311-017-0526-y Pages: 265-273
Article Type: Review

Medulloblastoma: Molecular Classification-Based Personal Therapeutics

1. Boston Children’s Hospital, Department of Neurology

2. Harvard Medical School

Correspondence to:
Scott L. Pomeroy
Email: scott.pomeroy@childrens.harvard.edu

Close

Abstract

Recent advances in cancer genomics have revealed 4 distinct subgroups of medulloblastomas, each with unique transcription profiles, DNA alterations and clinical outcome. Molecular classification of medulloblastomas improves predictions of clinical outcome, allowing more accurate matching of intensity of conventional treatments with chemotherapy and radiation to overall prognosis and setting the stage for the introduction of targeted therapies.

To access the full text, please Sign in

If you have institutional access, please click here

  • Online: Apr 6, 2017

Article Tools